Mostrar el registro sencillo del ítem
dc.contributor.author | Ramos Rincón, José Manuel | |
dc.contributor.author | Pérez-Belmonte, Luis M. | |
dc.contributor.author | Carrasco-Sánchez, Francisco Javier | |
dc.contributor.author | Jansen-Chaparro, Sergio | |
dc.contributor.author | De-Sousa-Baena, Mercedes | |
dc.contributor.author | Bueno-Fonseca, José | |
dc.contributor.author | Pérez-Aguilar, Maria | |
dc.contributor.author | Arévalo-Cañas, Coral | |
dc.contributor.author | Bacete Cebrian, Marta | |
dc.contributor.author | Méndez Bailón, Manuel | |
dc.contributor.author | Fiteni Mera, Isabel | |
dc.contributor.author | González García, Andrés | |
dc.contributor.author | Navarro Romero, Francisco | |
dc.contributor.author | Tuñón de Almeida, Carlota | |
dc.contributor.author | Muñiz Nicolás, Gemma | |
dc.contributor.author | Gonzáez Noya, Amara | |
dc.contributor.author | Hernández Milian, Almudena | |
dc.contributor.author | García-García, Gema-María | |
dc.contributor.author | Alcalá-Pedrajas, José-Nicolás | |
dc.contributor.author | Herrero García, Virginia | |
dc.contributor.author | Corral-Gudino, Luis | |
dc.contributor.author | Comas Casanova, Pere | |
dc.contributor.author | Meijide Mírguez, Héctor | |
dc.contributor.author | Casas Rojo, José Manuel | |
dc.contributor.author | Gómez Huelgas, Ricardo | |
dc.contributor.author | SEMI-COVID-19 Network | |
dc.date.accessioned | 2024-03-05T07:38:47Z | |
dc.date.available | 2024-03-05T07:38:47Z | |
dc.date.issued | 2021 | |
dc.identifier.other | http://hdl.handle.net/10668/17741 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/18872 | |
dc.description.abstract | Background: The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ?80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method: We conducted a nationwide, multicenter, observational study in patients ?80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results: Of the 2 763 patients ?80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions: We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality. | |
dc.language.iso | eng | |
dc.type.hasVersion | SMUR | |
dc.rights.uri | http://creativecommons.org/licenses/by-nd/4.0/ | * |
dc.subject | Age ≥ 80 | |
dc.subject | Cardiometabolic therapy | |
dc.subject | Coronavirus disease-2019 | |
dc.subject | Mortality | |
dc.subject | Type 2 diabetes | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Angiotensin Receptor Antagonists | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Cardiovascular Diseases | |
dc.subject.mesh | Diabetes Mellitus, Type 2 | |
dc.subject.mesh | Dipeptidyl-Peptidase IV Inhibitors | |
dc.subject.mesh | Female | |
dc.subject.mesh | Hospital Mortality | |
dc.subject.mesh | Hospitalization | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Hypoglycemic Agents | |
dc.subject.mesh | Male | |
dc.subject.mesh | SARS-CoV-2 | |
dc.title | Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19 | |
dc.type | research article | |
dc.rights.license | Attribution-NoDerivs 4.0 International | * |
dc.identifier.pubmedID | 33945610 | es_ES |
dc.format.volume | 76 | es_ES |
dc.format.number | 8 | es_ES |
dc.format.page | e102-e109 | es_ES |
dc.identifier.doi | 10.1093/gerona/glab124 | |
dc.identifier.e-issn | 1758-535X | es_ES |
dc.identifier.journal | The journals of gerontology. Series A, Biological sciences and medical sciences | es_ES |
dc.rights.accessRights | open access | es_ES |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |